| scholarly article | Q13442814 |
| P356 | DOI | 10.1164/RCCM.201702-0278OC |
| P8608 | Fatcat ID | release_xokhipte5fcdddlm4w2qwy5pli |
| P932 | PMC publication ID | 5649979 |
| P698 | PubMed publication ID | 28727491 |
| P50 | author | Nuala McGrath | Q42430120 |
| Mark Nicol | Q50636340 | ||
| Richard Lessells | Q56525222 | ||
| Graham Cooke | Q59488420 | ||
| Marie-Louise Newell | Q30668464 | ||
| P2093 | author name string | Peter Godfrey-Faussett | |
| P2860 | cites work | Impact of a novel molecular TB diagnostic system in patients at high risk of TB mortality in rural South Africa (Uchwepheshe): study protocol for a cluster randomised trial | Q36940706 |
| Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects | Q37671448 | ||
| Against all odds: diagnosing tuberculosis in South Africa | Q37945441 | ||
| Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. | Q38947214 | ||
| The economic burden of TB diagnosis and treatment in South Africa | Q39009157 | ||
| Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial | Q39520488 | ||
| Investigating the affordability of key health services in South Africa. | Q40092790 | ||
| Impact of point-of-care implementation of Xpert® MTB/RIF: product vs. process innovation. | Q41060035 | ||
| The impact of Xpert(®) MTB/RIF in sparsely populated rural settings. | Q41346870 | ||
| How point-of-care testing could drive innovation in global health | Q46841379 | ||
| ??? | Q26824091 | ||
| Impact of Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic Review of Study Methodologies | Q26767271 | ||
| Impact of Decentralized Care and the Xpert MTB/RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South Africa | Q28394564 | ||
| Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial | Q28545155 | ||
| Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis | Q28657913 | ||
| A systematic review of delay in the diagnosis and treatment of tuberculosis | Q33314674 | ||
| Simple sample size calculation for cluster-randomized trials | Q33644084 | ||
| A comparison of multidrug-resistant tuberculosis treatment commencement times in MDRTBPlus line probe assay and Xpert® MTB/RIF-based algorithms in a routine operational setting in Cape Town | Q33982095 | ||
| Effects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa | Q34076574 | ||
| Technologies for global health | Q34291969 | ||
| Dramatic increase in HIV prevalence after scale-up of antiretroviral treatment | Q34687399 | ||
| Population-level impact of same-day microscopy and Xpert MTB/RIF for tuberculosis diagnosis in Africa | Q34947034 | ||
| Implementation Research to Inform the Use of Xpert MTB/RIF in Primary Health Care Facilities in High TB and HIV Settings in Resource Constrained Settings | Q35647887 | ||
| The impact of new tuberculosis diagnostics on transmission: why context matters | Q36316501 | ||
| Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa | Q36424212 | ||
| The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF. | Q36907330 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tuberculosis | Q12204 |
| P304 | page(s) | 901-910 | |
| P577 | publication date | 2017-10-01 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Impact of Point-of-Care Xpert MTB/RIF on Tuberculosis Treatment Initiation. A Cluster-randomized Trial | |
| P478 | volume | 196 |
| Q92572142 | Building a tuberculosis-free world: The Lancet Commission on tuberculosis |
| Q88919197 | C-reactive protein as a screening test for HIV-associated pulmonary tuberculosis prior to antiretroviral therapy in South Africa |
| Q94495181 | Dynamics of within-host Mycobacterium tuberculosis diversity and heteroresistance during treatment |
| Q61804343 | Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis |
| Q90449369 | Impact of GxAlert on the management of rifampicin-resistant tuberculosis patients, Port Moresby, Papua New Guinea |
| Q90449390 | TB treatment delay associated with drug resistance and admission at Daru General Hospital in Papua New Guinea |
| Q61799745 | Test and Treat TB: a pilot trial of GeneXpert MTB/RIF screening on a mobile HIV testing unit in South Africa |
| Q57469995 | The Acid Fast Bacilli Smear: Hail and Farewell |
| Q42687193 | Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis |
| Q64892191 | Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. |
Search more.